Kutshanje, uNantong Chanyoo wenze elinye inqanaba elisembalini!Ngemizamo engaphezulu konyaka omnye, i-KDMF yokuqala ye-Chanyoo yamkelwe yi-MFDS.Njengomvelisi omkhulu weRosuvastatin Calcium eTshayina,sinqwenela ukuvula isahluko esitsha kwimarike yaseKorea.Kwaye ezinye iimveliso ziya kusungulwa kwiminyaka embalwa ezayo.

Kwakhona, ungabhekisa kwaye ufumane ulwazi lwethu kule webhusayithi:

https://nedrug.mfds.go.kr/pbp/CCBAC03

I-Rosuvastatin calcium ifanelekile kunyango lwe-adjuvant lwezigulana ezine-hypercholesterolemia yokuqala (uhlobo lwe-IIa, kuquka i-heterozygous family hypercholesterolemia) okanye i-mixed lipemia (uhlobo lwe-IIb) xa ukutya okanye unyango lokuzilolonga lungafanelekanga.Rosuvastatin calciumyinto ekhethiweyo ye-3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) i-reductase inhibitor.Ngokuthintela i-HMG-CoA reductase, inciphisa ukuhlanganiswa kweeseli zesibindi kunye nokugcinwa kwe-cholesterol, ngaloo ndlela i-Lower blood total cholesterol (TC) kunye ne-low-density lipoprotein cholesterol (LDL-C).

Ngokutsho kwedatha yeNewport, ukususela ngoJuni 30, i-2018 ukuya kuJuni 30, i-2019, ukuthengiswa kwehlabathi jikelele kwamalungiselelo e-rosuvastatin calcium kwakuyi-US $ 3.461 yezigidigidi, ukwehla konyaka-ngonyaka we-13%;ukuthengiswa kwehlabathi jikelele kwezixhobo ze-calcium ze-rosuvastatin kwakuyi-151.09 iitoni, Ukunyuka konyaka-ngonyaka we-14%

Thina,Changzhou Pharmaceutical Factory(umvelisi oncedisayo: uNantong Chanyoo Pharmatech Co., Ltd.) wazinikela kumthengisi omkhulu we-Rosuvastatin API.